NEW YORK -- Major League Baseball and the Major League Baseball Players Association today released the annual public report from the Joint Drug Prevention and Treatment Program's Independent Program Administrator. The Joint Drug Prevention and Treatment Program calls for a public report to be issued by December 1 of each year.
The accompanying report from the Independent Program Administrator, Jeffrey M. Anderson, M.D.,
covers the period from the beginning of the 2012-2013 off-season through the end of Major League
Baseball's 2013 Postseason.
2013 Public Report of Major League Baseball's Joint Drug Prevention and Treatment Program
This report covers the time from the beginning of the 2012-2013 Major League Baseball offseason to the end of the 2013 Major League Baseball post-season. As per agreement between Major League Baseball and the Major League Baseball Players Association, the following report is specific to Players who compose forty-man rosters for Major League Baseball Clubs.
1) The total number of drug tests that were conducted for the presence of Performance Enhancing Substances and/or Stimulants during the time listed above was 5,391 tests. The number of urine samples that were collected and analyzed for the presence of Performance Enhancing Substances and/or Stimulants was 4,022. The number of blood samples that were collected and analyzed for the presence of human growth hormone was 1,369.
2) Eight tests were reported by the testing laboratory for having an adverse analytical finding
that resulted in discipline. All were for Stimulants. The substances reported were as
3) 13 non-analytical positives resulted in discipline.
4) 122 Therapeutic Use Exemptions were granted. The diagnoses were as follows:
Attention Deficit Disorder: 119
Jeffrey M. Anderson, MD
Independent Program Administrator
Major League Baseball's Joint Drug Prevention and Treatment Program